Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 22;14(6):2513-2523.
doi: 10.18632/aging.203972. Epub 2022 Mar 22.

Ovarian reserve parameters and IVF outcomes in 510 women with poor ovarian response (POR) treated with intraovarian injection of autologous platelet rich plasma (PRP)

Affiliations

Ovarian reserve parameters and IVF outcomes in 510 women with poor ovarian response (POR) treated with intraovarian injection of autologous platelet rich plasma (PRP)

Yigit Cakiroglu et al. Aging (Albany NY). .

Abstract

The aim of the current study was to characterize ovarian reserve parameters and IVF outcomes in women with a history of poor ovarian response (POR) treated with intraovarian injection of autologous platelet rich plasma (PRP). Reproductive age women (N=510; age range 30-45yo) diagnosed with POR based on Poseidon criteria were included in the study. PRP treatment resulted in higher AFC, higher serum AMH, lower serum FSH, and a higher number of mature oocytes and cleavage and blastocyst stage embryos. After PRP injection, 22 women (4.3%) conceived spontaneously, 14 (2.7%) were lost to follow up, and 474 (92.9%) attempted IVF. Among women who attempted IVF, 312 (65.8%) generated embryos and underwent embryo transfer, 83 (17.5%) achieved a pregnancy, and 54 (11.4%) achieved sustained implantation/live birth (SI/LB). In total, of the 510 women with POR and mean age of 40.3, PRP resulted in improvement of ovarian reserve parameters, a pregnancy rate of 20.5% and SI/LB rate of 12.9%. Our findings suggest that PRP treatment may be considered in women with POR. For wider clinical application, its clinical efficacy will need to be demonstrated in prospective randomized clinical trials.

Keywords: in vitro fertilization; platelet rich plasma; poor ovarian response.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST: E.S. is a consultant for and receives research funding from the Foundation for Embryonic Competence.

Figures

Figure 1
Figure 1
Flowsheet of outcomes for all patients.

Similar articles

Cited by

References

    1. Seli E. Ovarian Aging. Semin Reprod Med. 2015; 33:375–6. 10.1055/s-0035-1567817 - DOI - PubMed
    1. Practice Committee of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org, and Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020; 114:1151–7. 10.1016/j.fertnstert.2020.09.134 - DOI - PubMed
    1. Kasapoğlu I, Seli E. Mitochondrial Dysfunction and Ovarian Aging. Endocrinology. 2020; 161:bqaa001. 10.1210/endocr/bqaa001 - DOI - PubMed
    1. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L, and ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011; 26:1616–24. 10.1093/humrep/der092 - DOI - PubMed
    1. Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, Esteves SC, Fischer R, Galliano D, Polyzos NP, Sunkara SK, Ubaldi FM, Humaidan P, and Poseidon Group (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number). A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016; 105:1452–3. 10.1016/j.fertnstert.2016.02.005 - DOI - PubMed